New POLARIS Phase I/II data presented at ASGCT show ETX101 gene therapy reducing seizures and improving neurodevelopment in children with SCN1A+ Dravet syndrome.

Throughout this three-part webinar series, experts from USP and industry will share first-hand experiences, case studies, and ...

Genomics and Harvard University have sued Element Biosciences, alleging that Element’s AVITI24™ multiomics platform, Teton ...

The EvoLVcell stable producer cell line generation platform reportedly reduces variability and produces fewer impurities.

Built around the packages Sprint, Flex, and Flex+, Gene Synthesis 2.0 introduces a streamlined, intuitive ordering experience ...

Researchers mapped more than 100 mutations that allow diverse HIV-1 strains to evade broadly neutralizing antibodies.

At ASGCT, the company will share data showing that its RNA achieves higher, more durable protein expression compared to other ...

EnGene (NASDAQ: ENGN) stock suffered a more-than-80% plunge this past week that reflects just how competitive the field is ...

There is no margin for error in the pharma and biopharma sectors. If the chain-identity breaks anywhere along the way, there ...

The FDA has granted accelerated approval to Regeneron Pharmaceuticals’ Otarmeni™ (lunsotogene parvec-cwha) as the first gene ...

Macrophages use cell‑volume changes to sense danger, reprogram gene expression, and heighten inflammatory and antiviral ...

Bayer has agreed to acquire Perfuse Therapeutics for up to $2.45 billion, in a deal designed to broaden the buyer’s ophthalmology pipeline with Perfuse’s sole pipeline drug and two clinical phase ...